Morning Research Covering Healthcare Sector: Hospira, Alkermes, Theravance, and Celsion

 Morning Research Covering Healthcare Sector: Hospira, Alkermes, Theravance,
                                 and Celsion

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

LONDON, December 10, 2013

LONDON, December 10, 2013 /PRNewswire/ --

On Monday, December 09, 2013, the U.S. equity market finished on a positive
note. The S&P 500 ended the day at 1,808.37, up 0.18%; the Dow Jones
Industrial Average closing at 16,025.53, up 0.03%; and the NASDAQ Composite
finishing at 4,068.75, up 0.15%. The S&P 500 Health Care Sector Index gained
0.19% to close at 638.95; and the S&P 500 Biotechnology Industry Index closed
0.50% higher at 2,796.27; and the same has surged 9.77% in the previous one
month and 12.52% in the last three months, outperforming the S&P 500, which
has gained 2.13% and 8.17% during the respective periods. Additionally, the
S&P 500 Pharmaceuticals Sub Industry Index edged 0.14% higher to close at
490.41. The major movers in the industry included Hospira Inc. (NYSE: HSP),
Alkermes PLC (NASDAQ: ALKS), Theravance Inc. (NASDAQ: THRX), and Celsion Corp.
(NASDAQ: CLSN). AAAResearchReports.com initiated preliminary technical
research on HSP, ALKS, THRX, and CLSN. These free reports are accessible by
signing today at:

http://www.aaaresearchreports.com/register/ 

Hospira Inc.'s stock rose 1.49% on Monday, closing the day at $42.19, after
oscillating between $41.65 and $42.50 during the trading session. A total of
1.16 million shares were traded, which is above the daily average volume of
0.81 million. The company's shares have advanced 4.92% in the previous three
trading sessions and 8.49% in the last one month, outperforming the S&P 500,
which has gained 0.87% and 2.13% during the respective periods. Moreover,
Hospira Inc.'s stock is trading near its 52-week high of $42.60 and also above
its 50-day and 200-day moving averages of $39.99 and $36.89, respectively. The
free technical analysis on HSP is available by signing up at:

http://www.AAAResearchReports.com/HSP121013.pdf

Alkermes PLC's stock edged 0.23% higher on Monday, tracking gains in the
broader market. The company's shares finished the day at $39.94, after
vacillating between $39.67 and $40.25 during the trading sessions. A total of
1.15 million shares were traded, which is above the daily average volume of
0.85 million. The company's shares have surged 16.55% in the previous three
months and 10.58% in the last one month, outperforming the S&P 500, which has
gained 8.17% and 2.13% during the respective periods. Furthermore, Alkermes
PLC's stock is trading above its 50-day and 200-day moving averages of $35.81
and $31.06, respectively. Register now to download free research on ALKS at:

http://www.AAAResearchReports.com/ALKS121013.pdf

Shares in Theravance Inc. fell 2.52% on Monday, ending the day at $36.40,
after fluctuating between $36.26 and $38.30 during the trading session. A
total of 2.05 million shares were traded, which is above the daily average
volume of 0.93 million. Despite Monday's pullback, the company's shares have
advanced 5.14% in the last one month, outperforming the S&P 500, which has
gained 2.13% during the same period. Additionally, Theravance Inc.'s stock is
trading above its 200-day moving average of $34.45. A free report on THRX can
be accessed by registering at:

http://www.AAAResearchReports.com/THRX121013.pdf

Celsion Corp.'s ended the day 2.60% lower at $3.75 on Monday, even as the US
equity market advanced. The company's shares fluctuated between $3.70 and
$3.84 during the trading session. A total of 0.19 million shares were traded,
which is below the daily average volume of 0.41 million. The company's shares
have declined 4.34% in the previous three trading sessions, underperforming
the S&P 500, which has gained 0.87% during the same period. Further, Celsion
Corp.'s stock is trading below its 50-day and 200-day moving averages of $4.58
and $5.01, respectively. Register with AAA Research Reports and download
research on CLSN for free at:

http://www.AAAResearchReports.com/CLSN121013.pdf

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE AAA Research Reports

Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID:
info@aaaresearchreports.com
 
Press spacebar to pause and continue. Press esc to stop.